Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 6/20 | 0.62 |
| ▸ | CA12 | O43570 | 10/20 | 0.43 |
| ▸ | CA1 | P00915 | 10/20 | 0.43 |
| ▸ | CA2 | P00918 | 10/20 | 0.43 |
| ▸ | CA4 | P22748 | 10/20 | 0.43 |
| ▸ | CA9 | Q16790 | 10/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5043372 | 0.92 | PTGER2 (0.71) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5043416 | 0.91 | PTGER2 (0.60) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399034 | 0.87 | PTGER2 (0.49) | PTGER2CA12CA1CA2CA9 | |
| SCHEMBL13398726 | 0.85 | PTGER2 (0.63) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399222 | 0.85 | PTGER2 (0.61) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399007 | 0.84 | PTGER2 (0.67) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5049397 | 0.84 | PTGER2 (0.49) | PTGER2CA12CA1CA2CA9 | |
| SCHEMBL13399301 | 0.84 | PTGER2 (0.87) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399008 | 0.84 | PTGER2 (0.62) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6058717 | 0.83 | PTGER2 (0.47) | PTGER2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105905-A1 | EP2 Agonists | PFIZER INC. | 2010-04-29 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | PTGER2 1/4885CA12 4207/4885CA1 4803/4885 |
| US-20100105905-A1 | EP2 Agonists | PTGER2, PTGER1, PTGIR | PTGER2 1/4885CA12 4207/4885CA1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.